1. Home
  2. ACB vs NGEN Comparison

ACB vs NGEN Comparison

Compare ACB & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aurora Cannabis Inc.

ACB

Aurora Cannabis Inc.

HOLD

Current Price

$3.72

Market Cap

232.3M

Sector

Health Care

ML Signal

HOLD

Logo NervGen Pharma Corp. Common stock

NGEN

NervGen Pharma Corp. Common stock

N/A

Current Price

$2.18

Market Cap

200.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ACB
NGEN
Founded
2013
2017
Country
Canada
Canada
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
232.3M
200.0M
IPO Year
2016
2018

Fundamental Metrics

Financial Performance
Metric
ACB
NGEN
Price
$3.72
$2.18
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$18.00
AVG Volume (30 Days)
1.5M
605.4K
Earning Date
06-17-2026
04-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.31
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.56
$1.58
52 Week High
$6.67
$5.93

Technical Indicators

Market Signals
Indicator
ACB
NGEN
Relative Strength Index (RSI) 54.25 56.99
Support Level $3.27 $1.62
Resistance Level $3.91 $2.32
Average True Range (ATR) 0.13 0.16
MACD -0.06 0.00
Stochastic Oscillator 3.75 63.60

Price Performance

Historical Comparison
ACB
NGEN

About ACB Aurora Cannabis Inc.

Aurora Cannabis Inc is focused on the production, distribution, and sale of cannabis products in Canada and internationally. The Company conducts the production, distribution, and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Its segments are Canadian Cannabis CGU, European Cannabis CGU, Australia Cannabis CGU, and New Zealand Cannabis CGU, with Canada generating majority revenue.

About NGEN NervGen Pharma Corp. Common stock

NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.

Share on Social Networks: